Botulinum toxin A (BoNT-A) paralyzes muscle by blocking acetylcholine release at the
synaptic junction. BoNT-A has shown its therapeutic effects in neurological disorders such …

BACKGROUND: Post-stroke spasticity is often one of the primary impairments addressed in
rehabilitation. However, limited guidance exists on the effectiveness of physical therapy (PT) …

Objective To develop an algorithm for the selection of adults with disabling spasticity for
treatment with intrathecal baclofen (ITB) and/or botulinum toxin type A (BoNT A). Methods A …

ABSTRACT The Guidelines for Stroke Rehabilitation are the result of a joint effort by the
Scientific Department of Neurological Rehabilitation of the Brazilian Academy of Neurology …

Despite the frequency of spasticity, robust diagnostic criteria and reliable assessment scales
are required. High-quality studies are needed to support the efficacy of current treatments for …

Objective Non-pharmacological adjunctive therapies can be used alongside botulinum toxin
injection to enhance its efficacy. The objective of this global study was to determine the …

Spasticity management should be provided within the context of a comprehensive person-
centered rehabilitation program. Furthermore, active goal setting for specific spasticity …

Background Current guidelines recommend intramuscular botulinum toxin type A (BoNT-A)
injection as first-line treatment for spasticity, a frequent and impairing feature of various …

Our objective was to provide expert consensus on best practices for anatomy teaching and
training on ultrasound-guided botulinum neurotoxin type A (BoNT-A) injection for specialists …

Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common
disabling consequence of many neurological diseases. Electrical stimulation of motor nerve …